SAN DIEGO, April 16, 2012 /PRNewswire/ -- Ambit Biosciences today announced that the company is scheduled to present at the 19th Annual Future Leaders in the Biotech Industry Conference at 8:30 a.m. EDT on Friday, April 20, 2012, at the Millennium Broadway Hotel in New York City. Michael A. Martino, Ambit's president and chief executive officer, will provide an overview of the company and an update about its clinical development programs, including quizartinib.
Quizartinib, formerly known as AC220, is being developed in collaboration between Ambit Biosciences and Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor. Quizartinib is currently under evaluation in a Phase 2 clinical trial as monotherapy treatment for adult and elderly patients with relapsed or refractory AML that have an internal tandem duplication (ITD) mutation in the FLT3 gene.
About Ambit Biosciences
Ambit Biosciences is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications. Ambit's lead compound, quizartinib (AC220), is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to quizartinib, Ambit's clinical pipeline includes AC430, an oral JAK2 inhibitor, and AC480, a pan-HER inhibitor. Ambit's preclinical portfolio includes, CEP-32496, a BRAF inhibitor licensed to Teva, and a proprietary CSF1R inhibitor program. For more information, visit www.ambitbio.com.
SOURCE Ambit Biosciences